Table 1.
Baseline characteristics of patients
| Center* | Number of patients |
Gender (male/female) |
Median age at diagnosis (range) |
GM peak eosinophil count ×109/L (range) |
|---|---|---|---|---|
| BRU | 22 | 12/10 | 48 (15–81) |
6.29 (2.0–16.7) |
| MUN | 8 | 5/3 | 43 (12–65) |
3.37 (1.5–8.32) |
| LEIC | 14 | 10/4 | 62 (30–78) |
10.52 (2.12–80.90) |
| BALT | 15 | 8/7 | 46 (23–85) |
5.86 (2.0–59.75) |
| CIN | 21 | 10/11 | 37 (15–56) |
5.45 (1.5–42.0) |
| MINN | 16 | 7/9 | 54 (9–69) |
5.91 (1.89–29.02) |
| BOS | 7 | 4/3 | 45 (23–59) |
7.30 (3.5–14.39) |
| SLC | 13 | 8/5 | 30 (6–74) |
11.34 (2.4–85.0) |
| BETH | 39 | 12/14 | 42 (16–69) |
8.98 (2.2–400) |
| BER | 14 | 6/8 | 54 (8–69) |
5.18 (1.5–340) |
| SUR | 19 | 9/10 | 43 (14–65) |
5.61 (1.7–31.60) |
| Total | 188 | 105/82 | 45 (6–85) |
6.602 (1.5–400) |
Gender distribution, median age at diagnosis, and geometric mean peak eosinophil count are provided for each of the participating centers: BRU=Erasme Hospital, Brussels, Belgium; MUN=Technical University of Munich, Munich, Germany; LEIC=University of Leicester, Leicester, UK ; BALT=Johns Hopkins Hospital, Baltimore, USA; CIN= Cincinnati Children’s Hospital Medical Center, Cincinnati, USA; MINN= Mayo Clinic, Rochester, USA; BOS=Harvard Medical School, Boston, USA; SLC= University of Utah, Salt Lake City, USA; BETH= Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, USA; BER=University of Bern, Bern, Switzerland; SUR=Hopital Foch, Suresnes, France